Target
RP1L1
1 abstract
Abstract
Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy.Org: Guangdong YueBei People's Hospital affiliated to Shantou University, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, The Second Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hospital of Xuzhou Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,